March 28, 2013 – Shire, a specialty biopharmaceutical company, is currently in clinical trials with a new iron chelator. Below, Shire responds to questions from CAF concerning the status of the drug, currently known as SPD602. How did Shire become interested in SPD602? In April 2012, Shire acquired FerroKin BioSiences, Inc. and the iron chelator […]